Andreas Strüngmann: Difference between revisions
No edit summary |
No edit summary |
||
| Line 15: | Line 15: | ||
==Personal life== |
==Personal life== |
||
Strüngmann currently has residences in [[Tegernsee]] and South Africa and is married with two children. |
Strüngmann currently has residences in [[Tegernsee]] and South Africa and is married with two children. In 2007, he and his wife established the Andreas and Susan Struengmann Foundation to support educational initiatives in the [[Western Cape]]. |
||
==See also== |
==See also== |
||
Revision as of 23:46, 7 April 2024
Andreas Strüngmann | |
|---|---|
| Born | 1950 (age 74–75) |
| Occupation | Entrepreneur |
| Known for | Co-founder of Hexal |
Andreas Strüngmann (born 1950) is a German physician[1] and businessman who founded generic drug maker Hexal AG ($1.6 billion sales during 2004) in 1986. It became Germany's second-largest generic drug producer.[2]
Career
In February 2005, Strüngmann and his twin brother Thomas sold Hexal and their 67.7 percent of U.S. Eon Labs to Novartis for $7.5 billion,[3] making its subsidiary Sandoz the largest generic-drug company in the world. At age 56, he subsequently accepted an executive position at Sandoz, working as head of regional operations in Europe, Africa and Asia-Pacific.[4]
In 2008, the Strüngmann brothers supported BioNTech with a €136.5 million seed investment in a €150 million round that enabled the founding of the company.[5] In 2023, they owned 43.5 percent of BioNTech through an investment vehicle called AT Impf, making their stake worth around $14 billion.[6]
Personal life
Strüngmann currently has residences in Tegernsee and South Africa and is married with two children. In 2007, he and his wife established the Andreas and Susan Struengmann Foundation to support educational initiatives in the Western Cape.
See also
References
- ^ Heide Neukirchen 21 March 2006), Familie Strüngmann: Papas, Pioniere und Piraten Manager Magazin.
- ^ Timmons, Heather & Wright, Tom. "Novartis to Buy Two Makers of Generics". The New York Times, 22 February 2005. Retrieved on 27 May 2013.
- ^ Forbes. "Andreas Strungmann - Forbes". March 2013. Retrieved on 27 May 2013.
- ^ Heather Timmons and Tom Wright (22 February 2005), Novartis to Buy Two Makers of Generics New York Times.
- ^ Denise Roland (15 May 2023), ‘Biotech is the ultimate impact investment’ — family offices can’t get enough of it Financial Times.
- ^ Denise Roland (15 May 2023), ‘Biotech is the ultimate impact investment’ — family offices can’t get enough of it Financial Times.
External links
| International | |
|---|---|
| National | |
 | This German business-related biographical article is a stub. You can help Wikipedia by expanding it. |